Fully liquid DTaP-IPV-Hib pediatric combination vaccine (Pediacel): a review of 18 years of clinical experience

Abstract

Safe and effective combination pediatric vaccines are necessary to simplify complex immunization schedules and to improve coverage and protection for children worldwide. We provide an overview of the 18 years of clinical and worldwide experience with DTaP-IPV-Hib (Pediacel^®), a unique fully liquid pentavalent vaccine (diphtheria [D], tetanus [T], acellular pertussis, inactivated poliovirus [IPV], Haemophilus influenzae type b [Hib]). Pediacel has demonstrated good and lasting immunogenicity in many populations, with differing primary series and booster schedules, and with a variety of coadministered vaccines. The acellular pertussis antigens have proven efficacy and real-world effectiveness. Clinical and post-marketing studies confirm the safety of Pediacel. Pediacel can be used for primary series and toddler booster doses, as well as in mixed pediatric vaccine schedules.

Keywords::

• effectiveness
• efficacy
• immunogenicity
• Pediacel^®
• pediatric combination vaccine
• pentavalent
• public health
• safety

Acknowledgements

The authors would like to thank F Boisnard, D Johnson, P Lashley and R Lersch for their valuable contributions during the preparation of this manuscript.

Financial & competing interests disclosure

D Reynolds is a former employee of Sanofi Pasteur and has received payments for consultancy services regarding vaccine research and development. E Vidor is a full-time employee of Sanofi Pasteur. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilized in the production of this manuscript from R Lersch (Sanofi Pasteur).

Key issues

• Pediacel is a unique fully liquid acellular pertussis-Haemophilus influenzae type b pentavalent pediatric combination vaccine that can help increase compliance and avoid administration errors.

• Pediacel has been extensively studied and can be used for primary series vaccination and as a third- or fourth-dose booster.

• Pediacel has demonstrated good and lasting immunogenicity in many different populations.

• The acellular pertussis antigens in Pediacel have proven efficacy and real-world effectiveness.

• Pediacel is licensed in 45 countries and has a proven safety record based on clinical data and 35 million doses distributed.

• Pediacel can be used for many schedules and with a variety of concomitant vaccines.

• Pediacel can be used as a booster dose for children vaccinated with a wP pertussis vaccine or a hexavalent vaccine primary series.